DICE Therapeutics (DICE) News Today

The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.

Y Intercept Hong Kong Ltd bought a new position in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 7,098 shares of the company's stock, value

Versor Investments LP purchased a new position in DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the company's stock, valued at approximat

SG Americas Securities LLC cut its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,713 shares of the company's stock after

Jump Financial LLC lessened its stake in shares of DICE Therapeutics, Inc. (NASDAQ:DICE - Free Report) by 41.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,311 shares of the company's stock afte

DICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) major shareholder Northpond Ventures Gp, Llc sold 2,492,871 shares of the firm's stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $46.50, for a total value of $115,918,501.50. Following the completion of the sale, the insider now directly owns 166,293 shares in the company, valued at approximately $7,732,624.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

DICE Therapeutics, Inc. (NASDAQ:DICE - Get Rating) - Stock analysts at HC Wainwright lowered their FY2027 earnings estimates for DICE Therapeutics in a report issued on Wednesday, June 21st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($5.82) f

The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.